Form 4: Dyne Therapeutics Director Dirk Kersten Reports Stock Sales Under 10b5-1 Plan

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) common stock through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Dirk Kersten, a director of Dyne Therapeutics, reported the sale of common stock on September 20 and 23, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (FCF IV) on April 9, 2024.
• On September 20, 2024, 78,940 shares were sold at a weighted average price of $36.45, and 471 shares were sold at a weighted average price of $37.01.
• On September 23, 2024, 36,221 shares were sold at a weighted average price of $35.19, and 4,610 shares were sold at a weighted average price of $36.33.
• After these transactions, Kersten indirectly beneficially owns 193,296 shares through FCF IV and 5,795,364 shares through ForDyne B.V.
• Kersten disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock sales by a director under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's future prospects.

Industry Context

Sales by company insiders are a common occurrence and are often conducted under pre-arranged trading plans like Rule 10b5-1 to avoid accusations of insider trading. The sales themselves don't necessarily indicate a negative outlook for the company, but the market may react depending on the size and frequency of such transactions.

Stakeholder Impact

• The stock sales could potentially impact shareholder sentiment, depending on the market's interpretation of insider transactions.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely minimal, as this is a routine transaction.

Key Dates